---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000003"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:29:53.316650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health reports Q4 2022 preliminary volumes up 18%; expects $6M cost savings

## Summary
- Q4 2022 OvaSuite test volume 5,643 (+18% YoY); full-year 2022 volume 21,424 (+23% YoY).
- Achieved previously provided Q4 cash utilization guidance of $6-8 million.
- Anticipates ~$6M in cost savings from staff reductions; does not expect material impact on growth.
- Expanded territories for top field reps; optimizing BioReference co-marketing agreement.

## SEC filing metadata
- accession: 0000926617-23-000003
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/awh-20230109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000003
- JSON: https://secwatch.observer/filing/0000926617-23-000003.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000003.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).
  - Period: the year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm
- Earnings Releases
  Aspira Women's Health Inc. updated its the three months ended December 31, 2021 guidance (reaffirmed).
  - Period: the three months ended December 31, 2021
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.